CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) announced that it will present a clinical and commercial update today on AP23573 - its novel mTOR inhibitor - at Windhover’s Therapeutic Alliances Series: Oncology Conference at the Westin Peachtree Plaza in Atlanta, Georgia. Windhover has chosen ARIAD’s lead oncology product candidate, AP23573, as one of the “top-ten most interesting cancer projects” available for partnering. ARIAD plans to commercialize AP23573 itself in the United States and partner AP23573 ex-U.S. as a Phase 3 product.
